Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer
| Autor: | Shusuke Akamatsu, Takahiro Inoue, Toshinari Yamasaki, Rihito Aizawa, Kenji Takayama, Genki Edward Sato, Takashi Kobayashi, Kiyonao Nakamura, Osamu Ogawa, Takashi Mizowaki |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty oligo-metastasis Health Toxicology and Mutagenesis medicine.medical_treatment 030232 urology & nephrology metastasis-directed therapy Disease-Free Survival Pelvis 03 medical and health sciences Prostate cancer 0302 clinical medicine medicine Adjuvant therapy Regular Paper Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis pelvic lymph nodal recurrence Aged Retrospective Studies Aged 80 and over Salvage Therapy Radiation Radiotherapy business.industry Prostatic Neoplasms Radiotherapy Dosage Middle Aged Prostate-Specific Antigen medicine.disease prostate cancer Neoadjuvant Therapy salvage pelvic radiation therapy Radiation therapy medicine.anatomical_structure Treatment Outcome 030220 oncology & carcinogenesis Lymphatic Metastasis Population study Hormonal therapy AcademicSubjects/SCI00960 Lymph Radiology Neoplasm Recurrence Local business Pelvic radiotherapy |
| Zdroj: | Journal of Radiation Research |
| ISSN: | 1349-9157 |
| Popis: | Although salvage external-beam radiation therapy (EBRT) is an attractive treatment option for pelvic lymph nodal recurrence (PeNR) in patients with prostate cancer (PCa), limited data are available regarding its long-term efficacy. This study examined the long-term clinical outcomes of patients who underwent salvage pelvic radiation therapy (sPRT) for oligo-recurrent pelvic lymph nodes after definitive EBRT for non-metastatic PCa. Patients who developed PeNR after definitive EBRT and were subsequently treated with sPRT at our institution between November 2007 and December 2015 were retrospectively analyzed. The prescribed dose was 45–50.4 Gy (1.8–2 Gy per fraction) to the upper pelvis, with up to 54–66 Gy (1.8–2 Gy per fraction) for recurrent nodes. Long-term hormonal therapy was used as neoadjuvant and/or adjuvant therapy. The study population consisted of 12 consecutive patients with PeNR after definitive EBRT (median age: 73 years). The median follow-up period was 58.9 months. The 5-year overall survival, PCa-specific survival, biochemical failure-free, clinical failure-free, and castration-resistant PCa-free rates were 82.5, 100.0, 62.3, 81.8, and 81.8%, respectively. No grade 2 or higher sPRT-related late toxicities occurred. In conclusion, more than half of the study patients treated with sPRT had a long-term disease-free status with acceptable morbidities. Moreover, most of the patients maintained hormonal sensitivity. Therefore, this approach may be a promising treatment method for oligo-recurrent pelvic lymph nodes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|